Glyburide, also referred to as glibenclamide, is a second-generation sulfonylurea approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. The medication is available as a generic formulation. It is an adjunct therapy along with diet and exercise for the management of diabetes.Standards of Medical Care in Diabetes 2022 update, sulfonylureas such as glyburide are considered one of multiple options for adjunct therapy, especially for patients limited by access to medications or costs.

For many years, glyburide has been studied off-label for the treatment of neonatal syndromic hyperglycemia for patients with Kir6.2 or SUR1 mutations.

Due to its overlap in the mechanism of action, recent studies have even begun to highlight low doses of glyburide as a possible agent for reducing intracranial pressure and cerebral edema.